Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off?

Bibliography

• Mcclellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-10
   PubMed Web of Science ®Google Scholar
• Hsu CY, Mcculloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504-10
   PubMed Web of Science ®Google Scholar
• Johnson CA, Levey AS, Coresh J, et al. Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors. Am Fam Physician 2004;70:869-76
   PubMed Web of Science ®Google Scholar
• KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47:S11-145
   PubMed Web of Science ®Google Scholar
• Fox CH, Brooks A, Zayas LE, et al. Primary care physicians′ knowledge and practice patterns in the treatment of chronic kidney disease: an Upstate New York Practice-based Research Network (UNYNET) study. J Am Board Fam Med 2006;19:54-61
   PubMed Web of Science ®Google Scholar
• Walker AM, Schneider G, Yeaw J, et al. Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol 2006;17:2293-8
   PubMedGoogle Scholar
• Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34
   PubMed Web of Science ®Google Scholar
• Khan SS, Kazmi WH, Abichandani R, et al. Health care utilization among patients with chronic kidney disease. Kidney Int 2002;62:229-36
   PubMed Web of Science ®Google Scholar
• Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37:348-55
   PubMed Web of Science ®Google Scholar
• Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548-54
   PubMed Web of Science ®Google Scholar
• Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 1992;60:390-6
   PubMed Web of Science ®Google Scholar
• Lim VS, Degowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 1989;110:108-14
   PubMed Web of Science ®Google Scholar
• Nurko S. Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleve Clin J Med 2006;73:289-97
   PubMed Web of Science ®Google Scholar
• Drueke TB, Eckardt KU, Frei U, et al. Does early anemia correction prevent complications of chronic renal failure? Clin Nephrol 1999;51:1-11
   PubMedGoogle Scholar
• Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12
   PubMed Web of Science ®Google Scholar
• Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004;141:95-101
   PubMed Web of Science ®Google Scholar
• United States Renal Data System: Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases,2003
   Google Scholar
• United States Renal Data System: Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases,2004
   Google Scholar
• United States Renal Data System: Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases,2006
   Google Scholar
• Hunsicker LG. The consequences and costs of chronic kidney disease before ESRD. J Am Soc Nephrol 2004;15:1363-4
   PubMed Web of Science ®Google Scholar
• Schoolwerth AC, Engelgau MM, Hostetter TH, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis 2006;3:A57
   PubMedGoogle Scholar
• Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 2002;162:1401-8
   PubMed Web of Science ®Google Scholar
• Eckardt KU, Mollmann M, Neumann R, et al. Erythropoietin in polycystic kidneys. J Clin Invest 1989;84:1160-6
   PubMed Web of Science ®Google Scholar
• Pavlovic-Kentera V, Clemons GK, Djukanovic L, Biljanovic-paunovic L. Erythropoietin and anemia in chronic renal failure. Exp Hematol 1987;15:785-9
   PubMedGoogle Scholar
• United States Renal Data System: Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases,2007
   Google Scholar
• Locatelli F, Aljama P, Bárány P, et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-47
   PubMed Web of Science ®Google Scholar
• Spinowitz B, Germain M, Benz R, et al. Epoetin Alfa Extended Dosing Study Group. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clin J Am Soc Nephrol 2008;3(4):1015-21
   PubMed Web of Science ®Google Scholar
• Jarsch M, Brandt M, Lanzendörfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-β determined by surface plasmon resonance and competition binding assay. Pharmacology 2008;81:63-9
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with Chronic Kidney Disease. Clin J Am Soc Nephrol 2006;1:1211-5
   PubMed Web of Science ®Google Scholar
• Fishbane S, Pannier A, Liogier X, et al. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol 2007;47:1390-7
   PubMed Web of Science ®Google Scholar
• Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol;2008;3:200-7
   PubMed Web of Science ®Google Scholar
• Veng-Pedersen P, Freise KJ, Schmidt RL, Widness JA. Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modeling. Comparison of C.E.R.A. and erythropoietin. J Pharm Pharmacol 2008;60:1321-34
   PubMed Web of Science ®Google Scholar
• Besarab A, Salifu MO, Lunde NM, et al. Ba16285 Study Investigators: Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clin Ther 2007;29(4):626-39
   PubMed Web of Science ®Google Scholar
• Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007;50(6):989-1000
   PubMed Web of Science ®Google Scholar
• Spinowitz B, Coyne DW, Lok CE, et al. RUBRA Study Investigators: C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol 2008;28(2):280-9
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Walker R, Provenzano R, et al. ARCTOS Study Investigators: C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008;3(2):337-47
   PubMed Web of Science ®Google Scholar
• Sulowicz W, Locatelli F, Ryckelynck JP, et al. PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2(4):637-46
   PubMed Web of Science ®Google Scholar
• Canaud B, Mingardi G, Braun J, et al. STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008;23(11):3654-61
   Google Scholar
• European Medicines Association. Scientific discussion: MIRCERA (methoxy polyethylene glycol-epoetin beta). Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/mircera/H-7 39-en6.pdf [Accessed 14 March 2009]
   Google Scholar
• European Medicines Association. Summary of product characteristics: MIRCERA (methoxy polyethylene glycol-epoetin beta). Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/mircera/H-7 39-PI-en.pdf [Accessed 14 March 2009]
   Google Scholar
• Provenzano R, Bhaduri S, Singh AK. PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005;64(2):113-23
   Google Scholar